

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/796,288 03/10/2004		Marlene M. Darfler	40970-0002	9373		
61263	7590	10/10/2006	EXAMINER			
PROSKAU			PETERSEN, CLARK D			
SUITE 400		A AVE, N.W.,		ART UNIT	PAPER NUMBER	
WASHING	TON, DC	20004	1657			

DATE MAILED: 10/10/2006

Please find below and/or attached an Office communication concerning this application or proceeding.



			Application	No.	Applicant(s)				
Office Action Summary			10/796,288		DARFLER ET AL.				
			Examiner		Art Unit				
			Clark D. Pet	ersen	1655				
Period fo	The MAILING DATE of this commun or Reply	ication app	ears on the o	over sheet with the c	orrespondence ad	Idress			
WHIC - Exter after - If NO - Failu Any r	CRTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M sions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comn period for reply is specified above, the maximum st- re to reply within the set or extended period for reply eply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	IAILING DA of 37 CFR 1.13 nunication. atutory period w will, by statute,	ATE OF THIS 66(a). In no event fill apply and will a cause the applica	S COMMUNICATION , however, may a reply be time expire SIX (6) MONTHS from ation to become ABANDONE	I. tely filed the mailing date of this c (35 U.S.C. § 133).				
Status				,					
1)⊠	Responsive to communication(s) file	ed on <i>10 Ma</i>	arch 2004						
•	Responsive to communication(s) filed on <u>10 March 2004</u> . This action is FINAL . 2b) This action is non-final.								
· · ·		<i>,</i> — .			secution as to the	e merits is			
٥,۵	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4) 🖂	Claim(s) 1-39 is/are pending in the a	application.							
, -	4a) Of the above claim(s) is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
6)									
	Claim(s) is/are objected to.								
8)	Claim(s) 1-39 are subject to restriction	on and/or e	election requ	irement.					
Applicati	on Papers								
9)	The specification is objected to by th	e Examiner	r.						
10)	The drawing(s) filed on is/are:	: a) <u> </u>	epted or b)	objected to by the E	Examiner.				
	Applicant may not request that any obje	ction to the c	drawing(s) be	held in abeyance. See	e 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including	the correcti	ion is required	I if the drawing(s) is obj	ected to. See 37 C	FR 1.121(d).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority u	ınder 35 U.S.C. § 119								
	Acknowledgment is made of a claim All b) Some * c) None of:				-(d) or (f).				
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
	the attached detailed office details				-				
Attachmen	t(s)								
1) D Notic	(PTO-413)								
	e of Draftsperson's Patent Drawing Review (F	PTO-948)	,	Paper No(s)/Mail Da Notice of Informal P					
	mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date		Č	6) Other:	Transcription of the company of the				

Art Unit: 1655

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-17, drawn to a method of preparing a biomolecule lysate from a histopathologically prepared specimen, classified in class 435, subclass 325, for example.
- II. Claim 18, drawn to a kit of reagents for preparing a biomolecule lysate from histopathologically prepared specimens, classified in class 435, subclass 40.5, for example.
- III. Claims 19-39, drawn to a method of binding biomolecule lysates to supports for analysis, classified in class 435, subclass 4, for example.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the product as claimed can be used in a materially different process of using that product. For example, detergents and proteolytic enzymes are routinely used to prepare fixed specimens such as embryos for tissue expression staining, rather than total lysis.

Art Unit: 1655

Inventions I and III are directed to related processes. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed have different functions. The function of invention I is to prepare a biomolecule lysate from a solid sample, whereas the function of Invention III is to detect molecules from a heterogeneous, uncharacterized sample. The inventions do not overlap in scope, because Invention I is directed to a method of processing a sample, whereas Invention III is directed to a method of analyzing the composition of a lysate. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants. Inventions II and III are directed to an unrelated product and process. Product and process inventions are unrelated if it can be shown that the product cannot be used in, or made by, the process. See MPEP § 802.01 and § 806.06. In the instant case, the product of Invention II, i.e. a kit for digesting a sample with a detergent and proteolytic enzyme, would serve no direct application in analyzing binding properties of molecules in a biological lysate, which is the process of Invention III.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Application/Control Number: 10/796,288

Art Unit: 1655

This application contains claims directed to the following patentably distinct species:

- A. The various detergents in the reaction buffer (see, e.g., claim 11)
- B. The various detergents for addition to the proteolytic enzyme (see, e.g., claim 12)
- C. The various proteolytic enzymes (see, e.g., claim 13)
- D. The various capture reagents (see, e.g., claim 21)
- E. The various support surfaces (see, e.g., claims 22 and 26)
- F. The various methods of spotting lysate onto support surface (see, e.g., claim 24)
- G. The various reagents of known binding affinity (see, e.g., claim 25)

The species are independent or distinct because they comprise different functions and structures requiring significantly non-overlapping searches.

Applicant is required under 35 U.S.C. 121 to elect a <u>single disclosed species for</u> each category A-F, i.e., one species for category A, applicable to both claims 11 and 12, one species for category B, etc., for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 9, 10, 20, and 23 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim

Application/Control Number: 10/796,288

Art Unit: 1655

is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Application/Control Number: 10/796,288 Page 6

Art Unit: 1655

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Clark D. Petersen whose telephone number is (571)272-5358. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571)272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Jen a Mikelry TERRY MCKELVEY, PH.D. SUPERVISORY PATENT EXAMINER